Envestnet Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Envestnet Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,176	Closed	-$732K	–	4194
2023 Q2	$732K	Buy	7,176 +2,993	+72%	+$283K	﹤0.01%	2981
2023 Q1	$380K	Sell	4,183 -4,860	-54%	-$285K	﹤0.01%	3324
2022 Q4	$344K	Buy	+9,043	New	+$311K	﹤0.01%	3338
2021 Q4	–	Sell	-2,626	Closed	-$264K	–	3968
2021 Q3	$264K	Sell	2,626 -7	-0.3%	-$821	﹤0.01%	3360
2021 Q2	$373K	Sell	2,633 -98	-4%	-$11.1K	﹤0.01%	3151
2021 Q1	$272K	Buy	2,731 +384	+16%	+$44.8K	﹤0.01%	3194
2020 Q4	$290K	Buy	+2,347	New	+$308K	﹤0.01%	2941
2020 Q3	–	Sell	-1,732	Closed	-$270K	–	3217
2020 Q2	$270K	Buy	+1,732	New	+$263K	﹤0.01%	2733
2020 Q1	–	Sell	-1,690	Closed	-$345K	–	3179
2019 Q4	$345K	Buy	+1,690	New	+$308K	﹤0.01%	2673

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Envestnet Asset Management's RETA Position: Q3 2023 in Review

Envestnet Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 7,176 shares — an estimated $732K sold.

Envestnet Asset Management first reported a position in RETA in Q4 2019 and held it in 9 quarters. The position peaked at $732K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Envestnet Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Envestnet Asset Management sold 7,176 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $732K.
Envestnet Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 9 quarters.
Envestnet Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $732K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Envestnet Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.